

PO203860

Érvényes

Ügyszám: **P0104993**

MSZH e-lajstrom

Bejelentés napja: 1999.10.26

Közzététel napja: 2002.05.28

HU P0104993

Unió elsőbbség: US60106739 - 1998.11.02

PCT bejelentés száma: US9925244

PCT közzététel száma (WO): 0025753

NSZO: A61K-009/24

Cím: **Eljárás és eszköz hatóanyagok kontrollált bevitelére**

Angol cím: METHOD AND DEVICE FOR CONTROLLED DELIVERY OF ACTIVE AGENTS


Bejelentő: ALZA Corporation, Mountain View, Kalifornia (US)

Feltaláló: Yam, Noymi, Sunnyvale, Kalifornia (US)

Bhatt, Padmanabh, Saratoga, Kalifornia (US)

Cruz, Evangeline G., Hayward, Kalifornia (US)

Képviselő: Szabó Zsolt, DANUBIA Szabadalmi és Védjegy Iroda Kft., Budapest (HU)



Kivonat (közzétételi):

A találmány tárgya hatóanyagot tartalmazó dózisforma (1), valamint kompresszált gyógyszerkészítményt, félígáteresztő falat (2) és tolófázist (5) tartalmazó dózisformából (1) hatóanyag ürülésének elősegítésére szolgáló eljárás.

A találmány szerinti dózisforma (1) tartalmaz üreg (3) meghatározó, legalább egy félígáteresztő tartománnyal és anyagában kialakított vagy kialakítható kiömlőnyílással (4) rendelkező falat (2); az üregben (3) a kiömlőnyílástól (4) távol a fal (2) félígáteresztő tartományaival közlekedően elrendezett tágulásra képes tolófázist (5); az üregben (3) a kiömlőnyílással (4) szomszédosan, a tágulásra képes tolófázissal (5) közvetlenül vagy közvetve érintkezően elrendezett hatóanyagfázist (6); továbbá a fal (2) belső felülete és legalább az üregben (3) lévő hatóanyagfázis (6) külső felülete között elrendezett ürülést segítő fázist (7).

A találmány szerinti dózisforma ürülést segítő fázissal (7) bevont kompresszált gyógyszerkészítményt tartalmaz.

A szóban forgó eljárás lényege, hogy a félígáteresztő fal (2) és a kompresszált gyógyszerkészítmény között ürülést segítő fázist (7) rendeznek el.

*** ABRA Frame253 ****

*** ABRA Frame254 ****

Intézkedések

4. Nemzetközi bejelentés közzététele (A2) (QJ)

Intézkedés kelte: 2002.03.27 meghirdetése: 2002.05.28 (BB9A Szabadalmi bejelentések közzététele)

9. Értesítés újdonságkutatás elvégzéséről (A3) (RV)

http://pipacsweb.hpo.hu/pia/pia04_03.htm?v=hunpia&q=B%3D%28%22ALZA%20... 2004.05.03.

Intézkedés kelte: 2003.01.27 meghirdetése: 2003.02.28 (EC9A Külön tájékoztatás újdonságkutatásról)

12. Ideiglenes szabadalmi oltalom újra érvénybe helyezése(2) (EI) ref.: 11

Intézkedés kelte: 2003.06.25 árvétele: 2003.06.26 meghirdetése: 2003.07.28 (NF4A Szabadalmi oltalom újra érvénybe helyezése)

BEST AVAILABLE COPY

HU P0104993

THOMSON
★
DELPHION

Log OutWork FilesSaved Searches

RESEARCHPRODUCTSINSIDE DELPHION

My AccountSearch: Quick/Number Boolean AdvancedDerwentHelp

No active trailSelect ORStop Tracking

Derwent Record

View: Expand DetailsGo to: Delphion Integrated View

☒ Email this to a friend

BEST AVAILABLE COPY

Derwent Title: Device for controlled delivery of high drug-loading compositions includes a flow-promoting layer between the semi-permeable layer and the drug layer

Derwent Original Title: WO0025753A2: CONTROLLED DELIVERY OF ACTIVE AGENTS

Derwent Assignee: BHATT P Individual
CRUZ E Individual
YAM N Individual
ALZA CORP Standard company
Other publications from ALZA CORP (ALZA)...

Derwent Inventor: BHATT P; CRUZ E; CRUZ E G; YAM N;
Derwent Accession/Update: 2000-365362 / 200380
Derwent IPC Code: A61K 0/00 ; A61K 9/20 ; A61K 9/22 ; A61K 9/24 ; A61K 9/44 ; A61K 31/496 ; A61K 47/02 ; A61K 47/10 ; A61K 47/12 ; A61K 47/14 ; A61K 47/32 ; A61K 47/34 ; A61K 47/38 ; A61K 47/42 ; A61K 25/24 ;

Derwent Classes: A96; B07; A11; A25;
Derwent Manual Codes: A12-V01(Medicines, pharmaceuticals) , B04-C02A(Cellulose and derivatives) , B04-C03C (Polyethers) , B04-N02(Animal protein/polypeptide (No sequence)) , B05-A01B(Group 1a, 2a, 3a excluding K, B, Ra) , B07-D03(Pyridine) , B07-D05(Piperidine) , B12-M03(Emulsion) , B12-M10A (Sustained release) , B14-J01A1(Antidepressant)







Derwent Abstract: (WO0025753A) **Novelty** - Use of a flow-promoting layer in a controlled delivery device to minimize drug retention is new.
Detailed Description - Controlled delivery dosage form (I) comprises:
(a) an outer wall which is semipermeable (or partially semipermeable) having an exit orifice formed or formable and which encloses a cavity;
(b) an expandable layer located in the cavity distal to the exit orifice;
(c) a drug layer located in the cavity adjacent to the exit orifice and in direct or indirect contact with the expandable layer;
(d) a flow-promoting layer interposed between the inner surface of the outer wall and at least the external surface of the drug layer.
ACTIVITY - None given.

MECHANISM OF ACTION - None given.

Use - (I) are particularly useful for controlled release of drugs in a high-loading oral dosage form for e.g. once-a-day administration. Incorporation of a flow-promoting layer enhances the smooth delivery of the drug by providing less friction at the interface between the drug composition and the semipermeable wall.

Advantage - The flow-promoting layer provides enhanced delivery of the drug composition reducing the amount of residual drug remaining undispensed in the device. Consequently the convention of adding extra drug to compensate for that undispensed is unnecessary, resulting in dosage forms which are physically smaller and more easy to swallow.

, Dwg. 0/0

Family:	Patent	Pub. Date	Derwent Update	Pages	Language	IPC Code
	 WO0025753A2 *	2000-05-11	200031	56	English	A61K 9/24
Des. States: (N) AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW (R) AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW						
Local apps.: <u>WO1999US0025244</u> Filed:1999-10-26 (99WO-US25244)						
	 NZ0511465A =	2003-10-31	200380		English	A61K 9/24
Local apps.: Based on <u>WO00025753</u> (WO 200025753) <u>NZ1999000511465</u> Filed:1999-10-26 (99NZ-0511465) <u>WO1999US0025244</u> Filed:1999-10-26 (99WO-US25244)						
JP2002528486W = 2002-09-03 200273 64 English A61K 9/22						
	 ZA0103524A =	2002-07-31	200271	71	English	A61K 0/00
Local apps.: Based on <u>WO00025753</u> (WO 200025753) <u>WO1999US0025244</u> Filed:1999-10-26 (99WO-US25244) <u>JP2000000579195</u> Filed:1999-10-26 (2000JP-0579195)						
Local apps.: <u>ZA2001000003524</u> Filed:2001-05-02 (2001ZA-0003524)						
	 HU0104993A2 =	2002-05-28	200249		English	A61K 9/24
Local apps.: Based on <u>WO00025753</u> (WO 200025753) <u>HU2001000004993</u> Filed:1999-10-26 (2001HU-0004993) <u>WO1999US0025244</u> Filed:1999-10-26 (99WO-US25244)						
	 US20020048600A1 =	2002-04-25	200233	25	English	A61K 9/20
Local apps.: <u>US2001000001116</u> Filed:2001-11-27 (2001US-0001116) Cont of <u>US1999000430837</u> Filed:1999-11-01 (99US-0430837) Provisional <u>US1998000106739P</u> Filed:1998-11-02 (98US-106739P)						
	 US6368626 =	2002-04-09	200227	24	English	A61K 9/22
Local apps.: <u>US1999000430837</u> Filed:1999-11-01 (99US-0430837)						

Provisional US1998000106739P Filed:1998-11-02 (98US-106739P)				
MX1004371A1 =	2002-03-01	200362	Spanish	A61K 9/24
Local apps.: Based on WO00025753 (WO 200025753) MX2001000004371 Filed:2001-05-02 (2001MX-0004371) WO1999US0025244 Filed:1999-10-26 (99WO-US25244)				
<input checked="" type="checkbox"/> CN1325301A =	2001-12-05	200223	English	A61K 9/24
Local apps.: CN1999000812981 Filed:1999-10-26 (99CN-0812981)				
<input checked="" type="checkbox"/> EP1126827A2 =	2001-08-29	200150	English	A61K 9/24
Des. States: (R) AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE Local apps.: Based on WO00025753 (WO 200025753) WO1999US0025244 Filed:1999-10-26 (99WO-US25244) EP1999000971310 Filed:1999-10-26 (99EP-0971310)				
KR1075676A =	2001-08-09	200211	English	A61K 9/24
Local apps.: KR2001000705529 Filed:2001-05-02 (2001KR-0705529)				
NO102168A =	2001-06-13	200141	NO_NO	A61K 9/24
Local apps.: NO2001000002168 Filed:2001-05-02 (2001NO-0002168) WO1999US0025244 Filed:1999-10-26 (99WO-US25244)				
<input checked="" type="checkbox"/> AU0012385A =	2000-05-22	200040	English	A61K 9/24
Local apps.: Based on WO00025753 (WO 200025753) AU2000000012385 Filed:1999-10-26 (2000AU-0012385)				

INPADOC
Legal Status:
Claims:
[Hide claims]:
Show legal status actions

- 1.. A dosage form for an active agent comprising: a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; a drug layer located within the cavity adjacent the exit orifice and in direct or indirect contacting relationship with the expandable layer; and a flow-promoting layer interposed between the inner surface of the wall and at least the external surface of the drug layer located within the cavity.
- 2.The dosage form of Claim 1 wherein the drug layer contains at least 40% by weight of drug based on the weight of the drug layer.
- 3.The dosage form of Claim 1 wherein the expandable layer comprises an osmotic agent.
- 4.The dosage form of Claim 3 wherein the flow-promoting layer comprises a material selected from hydrogels, gelatin, polyethylene oxides of less than 1 00,000 MW, hydroxyalkylcelluloses having number average molecular weights of between 9,500 and 1,250,000, and hydroxyalkyl alkyl1celluloses having number average molecular weights of between 80,000 to 850,000, and mixtures thereof.

5. The dosage form of Claim 1 wherein the flow-promoting layer is adapted to facilitate release of at least 80% of the drug in the drug layer to the environment of use.

6. An article of manufacture comprising a compressed drug composition overcoated with a flow-promoting layer.

7. The article of Claim 6 comprising an expandable layer in direct or indirect contact with the drug composition and forming a bilayer core with the drug composition, the bilayer core being overcoated with the flowpromoting layer.

8. The article of Claim 7 wherein the flow-promoting layer comprises a material selected from hydrogels, gelatin, polyethylene oxides of less than 1 00,000 MW, hydroxyalkylcelluloses having number average molecular weights of between 9,500 and 1,250,000, and hydroxyalkyl alkylcelluloses having number average molecular weights of between 80,000 to 850,000, and mixtures thereof.

9. The article of Claim 7 wherein the flow-promoting layer 1 5 comprises an hydroxypropyl cellulose.

10. A method of facilitating the release of a drug from a dosage form comprising a compressed drug composition, a semipermeable wall and a push layer, the method comprising interposing a flow promoting layer between the semipermeable wall and the compressed drug composition.

11. The method of Claim 10 wherein the flow promoting layer comprises a coating on the compressed drug composition prepared from a hydroxyalkyl cellulose and a lower alkanol. †

Priority Number:

Application Number	Filed	Original Title
US2001000001116	2001-11-27	CONTROLLED DELIVERY OF ACTIVE AGENTS
US1999000430837	1999-11-01	CONTROLLED DELIVERY OF ACTIVE AGENTS
US1998000106739P	1998-11-02	

Chemical Indexing Codes:

[Show chemical indexing codes](#)

Ring Index Numbers:

[Show ring index numbers](#)

Extended Polymer Index:

[Show extended polymer index](#)

Specific Compound Numbers:
Registry Numbers:

[Show specific compounds](#)

03[M1]:2044U
05[M2]:2020U

Unlinked Registry Numbers:
Related Accessions:

2020U 2044U

Accession Number	Type	Derwent Update	Derwent Title
C2000-110260	C		
1 item found			

⌕ Title Terms:

DEVICE CONTROL DELIVER HIGH DRUG LOAD COMPOSITION FLOW PROMOTE LAYER SEMI PERMEABLE LAYER
DRUG LAYER

[Pricing](#) [Current charges](#)

Derwent Searches: [Boolean](#) | [Accession/Number](#) | [Advanced](#)

Data copyright Thomson Derwent 2003

Copyright © 1997-2004
The Thomson Corporation

[Subscriptions](#) | [Web Seminars](#) | [Privacy](#) | [Terms & Conditions](#) | [Site Map](#) | [Contact Us](#) | [Help](#)